Anticoagulant Therapy in End Stage Renal Disease on Hemodialysis: A Comprehensive Systematic Review
Keywords:
Anti platelet medications, anti coagulant therapy, hemodialysisAbstract
Background: =We aimed to investigate the utilization of AC medications among patients who undergo hemodialysis (HD). We performed a systematic review and meta-analysis of observational studies on AC medications used in HD therapy. Methods: The review adhered to PRISMA 2020 standards and analyzed full-text English literature from 2014 to 2024. It excluded editorials, review papers from the same journal, and submissions lacking a DOI. Literature sources included PubMed, SagePub, SpringerLink, and Google Scholar. Result: After three rounds of screening, five articles directly relevant to the systematic review were selected for full-text reading and analysis. Conclusion: AC medications are given in HD patients with high cardiovascular commorbidities to increase vascular patency and prevent thrombosis. Aspirin and P2Y12 inhibitors (PI) such as clopidogrel are commonly used. AC medications might cause shortened longevity of AV access for HD patients. The benefits of AC therapy for cardiovascular protection needs to be evaluated along with its possible effect on AVG outcomes.
References
Locham S, Beaulieu RJ, Dakour-Aridi H, Nejim B, Malas MB. Role of antiplatelet therapy in the durability of hemodialysis access. J Nephrol. 2018 Aug;31(4):603–11.
Wang Q, Xie X, Xu G. The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis. BMC Nephrol. 2020 Dec;21(1):106.
Viecelli AK, Mori TA, Roy‐Chaudhury P, Polkinghorne KR, Hawley CM, Johnson DW, et al. The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. Seminars in Dialysis. 2018 May;31(3):244–57.
Nagaraj A, Skummer PT, Gunasekaran V, Johnson C, Roza A, Klinger D, et al. Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy. Cardiovasc Intervent Radiol. 2023 Feb;46(2):204–8.
Collette C, Clerc-Urmès I, Laborde-Castérot H, Frimat L, Ayav C, Peters N, et al. Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk. Pharmacoepidemiology and Drug Safety. 2016;
Shimizu A, Sonoda S, Muraoka Y, Setoyama K, Inoue K, Miura T, et al. Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients. Journal of Cardiology. 2019 Jun;73(6):470–8.
Yeh CH, Huang TS, Wang YC, Huang PF, Huang TY, Chen TP, et al. Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity. 2017;
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1–127.
Published
Issue
Section
License
Copyright (c) 2024 Jessica, Utomo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
